ArticleFrontiers in oncology2025
Clinicopathological features and risk factors for local recurrence of breast phyllodes tumors: a dual-center, 12-year, retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To clarify the risk factors of phyllodes tumor (PT) for local recurrence (LR). Methods: Data from 829 patients with pathologically confirmed benign, borderline and malignant PT of the breast, diagnosed from between 2011 to 2023, were retrieved from the electronic databases of the First Hospital of Jilin University and the First Affiliated Hospital of Xi'an Jiaotong University. Kaplan-Meier curves and Cox proportional-hazards model were conducted to determine the independent risk factors for LR in each group. Results: Of 829 PT patients, 634 (76.5%), 142 (17.1%), and 53 (6.4%) were diagnosed with benign, borderline, and malignant PT, respectively. The LR rates were 5.4%, 9.9%, 13.2%, respectively. The median patient age was 38 years and the median follow-up time was 2.8 (range, 0.2-12.1 years). Of these patients, 13 (2.1%) were diagnosed with benign bilateral PT. Multivariate analysis identified bilateral involvement as a risk factor for LR of benign PT ( Conclusions: Bilateral PT was a risk factor for LR of benign PT, young age (≤35 years) was associated with poor prognosis of borderline PT, BCS were high risk factors for LR of malignant PT. This study identifies LR risk factors based on tumor grading, which contributes to individualized clinical risk assessment. Future research could further explore how to incorporate these factors into clinical decision-making models for PT and other soft tissue tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.